Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 2Lymphoma, Non-Hodgkin 2

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 49Radiotherapy 47Docetaxel 42Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Imatinib Mesylate 14Drug Therapy 14Irinotecan 13Filgrastim 13Zoledronic Acid 12Trastuzumab 12Radiosurgery 12Erlotinib Hydrochloride 12Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Terminated × galiximab × Clear all
NCT00384150 2015-11-26

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Biogen

Phase 3 Terminated
16 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT00363636 2015-10-02

A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Biogen

Phase 3 Terminated
340 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡